Ex vivo studies showed that CD19 CAR-T cells efficiently and specifically eliminated RUNX1-mutated BP-CML blasts, affecting both lymphoid and myeloid compartments. Here, CD19 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.